Albemarle Corp. (ALB) 10-K Red Flags
Risk signals extracted deterministically from Albemarle Corp.’s SEC 10-K/10-Q XBRL filings — no LLM, every finding cites the underlying data.
Detected red flags (9)
- Gross margin expansion: Gross margin expanded +11.8%pp (from 1.2% to 13.0%), indicating improved pricing power, cost efficiency, or favorable product mix.
- Deferred revenue growing — future revenue visibility: Deferred revenue grew +4301.4% to $93.1M, providing forward revenue visibility. This is a positive leading indicator for subscription or contract-based businesses.
- Endogenous analysis: 2 positive signal(s) versus 0 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- 16 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- Revenue declined **+4.4%** YoY to $5.14B.
- 5-year revenue CAGR **+9.1%**; 10y CAGR +7.5%.
- Market cap $15.88B at $134.59 per share.
- FCF DCF intrinsic value ≈ $86.97 → implied downside +35.4%.
Filings & ownership
- Latest annual report (10-K) filed Feb 11, 2026.
- Latest quarterly report (10-Q) filed Aug 5, 2026.
- 18 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Albemarle Corp.; broad institutional reporting.
- Recent filers include TIDE POINT CAPITAL MANAGEMENT, LP, MASTERS CAPITAL MANAGEMENT LLC, MD SASS INVESTORS SERVICES INC.
- 20 recent 13G passive institutional ownership notices.
Full ALB analyst report
Valuation (DCF & Graham), technicals, macro exposure, risk scorecard and 13F/13D ownership.
View full report →Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.